MuLV IN mutants responsive to HDAC inhibitors enhance transcription from unintegrated retroviral DNA
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
For Moloney murine leukemia virus (M-MuLV), sustained viral infections require expression from an integrated provirus. For many applications, non-integrating retroviral vectors have been utilized to avoid the unwanted effects of integration, however, the level of expression from unintegrated DNA is significantly less than that of integrated provirus. We find that unintegrated DNA expression can be increased in the presence of HDAC inhibitors, such as TSA, when applied in combination with integrase (IN) mutations. These mutants include an active site mutation as well as catalytically active INs bearing mutations of K376 in the MuLV C-terminal domain of IN. MuLV IN K376 is homologous to K266 in HIV-1 IN, a known substrate for acetylation. The MuLV IN protein is acetylated by p300 in vitro, however, the effect of HDAC inhibitors on gene expression from unintegrated DNA is not dependent on the acetylation state of MuLV IN K376.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 2×
“…by IN K376R indicated the global target site preference with respect to transcriptional start sites and CpG island did not differ significantly from that published in WT MuLV (Wu et al., 2003), eliminating chromosomal positional effects as the cause for decreased gene expression (data not shown).”
BackgroundHIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells
Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., & Debyser, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209278200 · Cited by 704 · cited 2×
“, 1993), and the cellular host factor LEDGF, present in HIV (Cherepanov et al., 2003) but not MuLV (Llano et al.”
BackgroundRetroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 8×
“These results indicate that at least one acetylation site maps within the MuLV IN CTD. Characterization of MuLV IN mutants Sequence homology is low across the CTDs of various retroviral INs, however, structurebased sequence alignments between prototype foamy virus (PFV) (Hare et al., 2010b), HIV-1 (Chen et al., 2000;…”
BackgroundInfluentialEngelman, A., & Craigie, R. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6361-6369.1992 · Cited by 519 · cited 1×
“IN consists of three distinct domains as determined by limited proteolysis (Engelman and Craigie, 1992): the Nterminal Zn2+ binding domain (NTD), catalytic core domain (CCD), and the C-terminal domain (CTD).”
BackgroundBukrinsky, M. I., Sharova, N., McDonald, T. L., Pushkarskaya, T., Tarpley, W. G., & Stevenson, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6125 · Cited by 451
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication
Engelman, A., Englund, G., Orenstein, J. M., Martin, M. A., & Craigie, R. (1995) · Journal of Virology · doi:10.1128/jvi.69.5.2729-2736.1995 · Cited by 445
Craigie, R., Fujiwara, T., & Bushman, F. (1990) · Cell · doi:10.1016/0092-8674(90)90126-y · Cited by 409 · cited 2×
“Various in vitro assays have demonstrated that the IN protein alone is sufficient to catalyze both the 3’ processing and strand transfer reactions (Craigie et al., 1990; Katz et al., 1990), however, in vivo, additional viral and cellular proteins associate with the DNA and IN protein to form the functional pre-integra…”
BackgroundChen, J. C.-H., Krucinski, J., Miercke, L. J. W., Finer-Moore, J. S., Tang, A. H., Leavitt, A. D., & Stroud, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150220297 · Cited by 404 · cited 1×
“…the CTDs of various retroviral INs, however, structurebased sequence alignments between prototype foamy virus (PFV) (Hare et al., 2010b), HIV-1 (Chen et al., 2000; Hare et al., 2010b; Krishnan et al., 2010) and MuLV INs (P. Rossi personal communication) reveal that K370 in PFV and K266 in…”
BackgroundKatz, R. A., Merkel, G., Kulkosky, J., Leis, J., & Skalka, A. M. (1990) · Cell · doi:10.1016/0092-8674(90)90290-u · Cited by 346 · cited 2×
“Various in vitro assays have demonstrated that the IN protein alone is sufficient to catalyze both the 3’ processing and strand transfer reactions (Craigie et al., 1990; Katz et al., 1990), however, in vivo, additional viral and cellular proteins associate with the DNA and IN protein to form the functional pre-integra…”
BackgroundMolecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance
Hare, S., Vos, A. M., Clayton, R. F., Thuring, J. W., Cummings, M. D., & Cherepanov, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010246107 · Cited by 305 · cited 8×
“These results indicate that at least one acetylation site maps within the MuLV IN CTD. Characterization of MuLV IN mutants Sequence homology is low across the CTDs of various retroviral INs, however, structurebased sequence alignments between prototype foamy virus (PFV) (Hare et al., 2010b), HIV-1 (Chen et al., 2000;…”
BackgroundInfluentialLlano, M., Vanegas, M., Fregoso, O., Saenz, D., Chung, S., Peretz, M., & Poeschla, E. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.17.9524-9537.2004 · Cited by 305
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249 · cited 19×
“The need to establish a transcriptionally active state in the LTR of the provirus in the normal life cycle has also been suggested (Bruce et al., 2008).”
BackgroundInfluentialSequence and spacing requirements of a retrovirus integration site
Colicelli, J., & Goff, S. P. (1988) · Journal of Molecular Biology · doi:10.1016/0022-2836(88)90378-6 · Cited by 198 · cited 1×
“…we quantified minus strand strong stop products (MSSS), plus strand extension products (PSE), and 2-LTR circle junctions, a deadend product known to increase in quantity in the presence of defective IN proteins (Colicelli and Goff, 1985, 1988; Donehower and Varmus, 1984; Roth et al., 1990).”
BackgroundTransient Gene Expression by Nonintegrating Lentiviral Vectors
Nightingale, S. J., Hollis, R. P., Pepper, K. A., Petersen, D., Yu, X.-J., Yang, C., Bahner, I., & Kohn, D. B. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.008 · Cited by 192
Integrase-defective lentiviral vectors: Progress and applications
Banasik, M. B., & McCray, P. B. (2010) · Gene Therapy · doi:10.1038/gt.2009.135 · Cited by 129
Chen, H., Wei, S.-Q., & Engelman, A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17358 · Cited by 103
A large nucleoprotein assembly at the ends of the viral DNA mediates retroviral DNA integration
Wei, S., Mizuuchi, K., & Craigie, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.24.7511 · Cited by 102
Rahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
A Large U3 Deletion Causes Increased In Vivo Expression from a Nonintegrating Lentiviral Vector
Bayer, M., Kantor, B., Cockrell, A., Ma, H., Zeithaml, B., Li, X., McCown, T., & Kafri, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.199 · Cited by 94
Mohammed, K. D., Topper, M. B., & Muesing, M. A. (2011) · Journal of Virology · doi:10.1128/jvi.02374-10 · Cited by 44
Steinrigl, A., Nosek, D., Ertl, R., Günzburg, W. H., Salmons, B., & Klein, D. (2007) · Virology · doi:10.1016/j.virol.2006.11.037 · Cited by 13 · cited 1×
“A catalytic site mutant (D184N) was also included as a control for IN defective in integration (Steinrigl et al., 2007).”
Background
Cited by
BET proteins promote efficient murine leukemia virus integration at transcription start sites
Sharma, A., Larue, R. C., Plumb, M. R., Malani, N., Male, F., Slaughter, A., Kessl, J. J., Shkriabai, N., Coward, E., Aiyer, S. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307157110 · Cited by 193
“To delineate the Brd3(1-726) segments (Fig.”
BackgroundResultInfluentialSelf-citationNP220 mediates silencing of unintegrated retroviral DNA
Zhu, Y., Wang, G. Z., Cingöz, O., & Goff, S. P. (2018) · Nature · doi:10.1038/s41586-018-0750-6 · Cited by 123
Aiyer, S., Swapna, G. V. T., Malani, N., Aramini, J. M., Schneider, W. M., Plumb, M. R., Ghanem, M., Larue, R. C., Sharma, A., Studamire, B., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku175 · Cited by 72
Self-citationAiyer, S., Swapna, G. V. T., Ma, L.-C., Liu, G., Hao, J., Chalmers, G., Jacobs, B. C., Montelione, G. T., & Roth, M. J. (2021) · Structure · doi:10.1016/j.str.2021.01.010 · Cited by 35
Self-citationWinans, S., & Goff, S. P. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1009147 · Cited by 29
Metadata
- Authors
- Schneider, W. M., Wu, D.-T., Amin, V., Aiyer, S., & Roth, M. J.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 426
- Issue
- 2
- Pages
- 188-196
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W1964106615
- Cited by
- 33
- References
- 22
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.